{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:43:36Z","timestamp":1788914616909,"version":"build-2803163510"},"reference-count":49,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-alcoholic fatty liver disease (NAFLD), now increasingly termed metabolic dysfunction-associated steatotic liver disease (MASLD), is a growing cause of chronic liver disease with limited treatment options. Glucagon-like peptide-1 (GLP-1) receptor agonists, approved for type 2 diabetes and obesity, possess metabolic effects that may render them suitable for treating NAFLD and metabolic dysfunction-associated steatohepatitis (MASH). To evaluate the therapeutic effects of GLP-1 receptor agonists in adults with NAFLD, non-alcoholic steatohepatitis (NASH), MASLD, or MASH. PubMed, Scopus, Embase, and the Cochrane Library were systematically searched using keywords related to NAFLD and GLP-1 receptor agonists. Given heterogeneity in populations, designs, and outcomes, findings were synthesized narratively. The review is registered with PROSPERO (CRD420261337353). Twelve studies met the inclusion criteria. The most consistent outcome was a reduction in hepatic fat, seen with semaglutide, liraglutide, dulaglutide, and beinaglutide. Improvements in liver enzymes, particularly alanine aminotransferase, were less consistent and best regarded as supportive rather than definitive evidence of histological improvement. Histological benefits were strongest for steatohepatitis resolution in non-cirrhotic MASH. Fibrosis findings were mixed, with the greatest benefit in F2\u2013F3 MASH and limited improvement in established cirrhosis. GLP-1 receptor agonists were generally well tolerated, with gastrointestinal symptoms the most common adverse effects. GLP-1 receptor agonists show promising liver-related benefits in NAFLD and MASH, particularly in obesity, type 2 diabetes, or earlier-stage disease. Their effects on advanced fibrosis and long-term outcomes remain uncertain, warranting larger, longer-term studies.<\/jats:p>","DOI":"10.3390\/ijms27125618","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:09:17Z","timestamp":1782270557000},"page":"5618","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic Effects of Glucagon-like Peptide-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: A Systematic Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3090-5803","authenticated-orcid":false,"given":"Dina","family":"Mahoon","sequence":"first","affiliation":[{"name":"School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen 15503, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6916-1586","authenticated-orcid":false,"given":"Fares","family":"Kellany","sequence":"additional","affiliation":[{"name":"Research Department, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen 15503, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9177-8452","authenticated-orcid":false,"given":"Imad","family":"Khan","sequence":"additional","affiliation":[{"name":"Research Department, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen 15503, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4122-082X","authenticated-orcid":false,"given":"Somieya","family":"Khan","sequence":"additional","affiliation":[{"name":"Research Department, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen 15503, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5762-3917","authenticated-orcid":false,"given":"Alexandra E.","family":"Butler","sequence":"additional","affiliation":[{"name":"School of Medicine, Royal College of Surgeons in Ireland-Medical University of Bahrain, Busaiteen 15503, Bahrain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2024","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S2468-1253(26)00011-7","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 1990\u20132023, and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2023","volume":"11","author":"Kim","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_4","first-page":"e86963","article-title":"Pathological evolution and internal medicine management of nonalcoholic fatty liver disease in the era of metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Hashim","year":"2025","journal-title":"Cureus"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11892-024-01558-y","article-title":"NAFLD no more: A review of current guidelines in the diagnosis and evaluation of metabolic dysfunction-associated steatotic liver disease","volume":"25","author":"Kaylan","year":"2024","journal-title":"Curr. Diabetes Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Hu, Z., Zheng, Y., Li, Y., Wang, X., and Zhang, L. (2026). The mechanisms of GLP-1 receptor agonists in liver diseases. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1754721"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 receptor agonists in non-alcoholic fatty liver disease: Current evidence and future perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Deng, Y., Li, Y., Zhang, X., Wang, J., and Chen, L. (2024). Targeting mitochondrial homeostasis in the treatment of non-alcoholic fatty liver disease. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1463187"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: Randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: An updated meta-analysis of 501,022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2337\/dc16-1787","article-title":"Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: A call to action","volume":"40","author":"Bril","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat. Metab."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/apt.70516","article-title":"Clinical trial: Semaglutide versus placebo in NIT-assessed MASH\u2014A multicenter randomised placebo-controlled trial (SAMARA)","volume":"63","author":"Ajmera","year":"2026","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1080\/03007995.2025.2596430","article-title":"Changes in liver enzymes and cardiometabolic markers in individuals with obesity and metabolic dysfunction-associated steatohepatitis treated with semaglutide","volume":"41","author":"Albarmawi","year":"2025","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e70447","DOI":"10.1111\/liv.70447","article-title":"GLP-1 receptor agonists and liver fibrosis progression in MASLD and type 2 diabetes: Target trial emulation using propensity score matching","volume":"45","author":"Choi","year":"2025","journal-title":"Liver Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/dom.15359","article-title":"Efficacy of beinaglutide in the treatment of hepatic steatosis in type 2 diabetes patients with nonalcoholic fatty liver disease: A randomized, open-label, controlled trial","volume":"26","author":"Fan","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1111\/dom.13007","article-title":"Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial","volume":"19","author":"Khoo","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/08971900241253661","article-title":"Impact of GLP-1 receptor agonist use in patients with steatotic liver disease and type 2 diabetes: A retrospective cohort study","volume":"37","author":"Wood","year":"2024","journal-title":"J. Pharm. Pract."},{"key":"ref_28","first-page":"100092","article-title":"Effects of liraglutide on non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: A randomized controlled study","volume":"2","author":"Zhang","year":"2020","journal-title":"JHEP Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/hep.27678","article-title":"Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration joint workshop","volume":"61","author":"Sanyal","year":"2015","journal-title":"Hepatology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"518","DOI":"10.21037\/hbsn-2021-13","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: New insights from subcutaneous semaglutide","volume":"10","author":"Mantovani","year":"2021","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1038\/s41401-021-00836-9","article-title":"GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis","volume":"43","author":"Chen","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/dom.13553","article-title":"Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhepr.2019.08.002","article-title":"Non-alcoholic fatty liver disease in lean individuals","volume":"1","author":"Albhaisi","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/cld.930","article-title":"NAFLD in lean Asians","volume":"16","author":"Eslam","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Purnomo, H.D., Adiwinata, R., Permatadewi, C.O., Hutami, H.T., and Indiarso, D. (2025). The global landscape of lean metabolic dysfunction-associated steatotic liver disease: Insight from Asia and the West. Front. Gastroenterol., 4.","DOI":"10.3389\/fgstr.2025.1699508"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: A multicentre, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kopanos, S., Hoyer, A., Stoye, F.V., Feldkamp, J., Pouwels, S., and Pape-K\u00f6hler, C. (2026). Metabolic and bariatric surgery in MAFLD: A meta-analysis of endocrine outcomes, fibrosis remission, and postoperative complications. Surg. Obes. Relat. Dis.","DOI":"10.1016\/j.soard.2026.03.020"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.32358","article-title":"Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery","volume":"76","author":"Pais","year":"2022","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40519-025-01770-z","article-title":"The role of glucagon-like peptide-1 receptor agonists in weight regain treatment or prevention after bariatric surgery: A systematic review and meta-analysis","volume":"30","author":"Mousavi","year":"2025","journal-title":"Eat. Weight Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00423-025-03831-4","article-title":"GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: A systematic review and meta-analysis","volume":"410","author":"Tan","year":"2025","journal-title":"Langenbecks Arch. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5618\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:35:16Z","timestamp":1782272116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27125618"],"URL":"https:\/\/doi.org\/10.3390\/ijms27125618","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}